John Wilding trained in medicine in Southampton and the Hammersmith Hospital, London, where he also undertook three years laboratory-based research into the neurobiology of obesity and diabetes. He currently works at the University Hospital Aintree, Liverpool and was appointed Professor of Medicine in 2005. He leads a clinical research group working in the field of Obesity, Diabetes and Endocrinology at the University of Liverpool, UK. Professor Wilding is a Fellow of the Royal College of Physicians.

His areas of clinical interest and expertise include type 2 diabetes and obesity where the focus of his research team centres on developing new treatments and strategies to reduce the burden of diabetes and obesity-related disease.

Professor Wilding has published over 350 original papers, chapters and review articles (ORCID ID 0000-0003-2839-8404; H index 69), which include clinical trials in diabetes and obesity, adipocyte biology and studies of metabolism. His teaching and assessment experience include being Systems Lead for years 1 and 2 for the MBChB Endocrinology at the University of Liverpool and a Founding Fellow of the World Obesity Federation Strategic Centre for Obesity Professional Education (SCOPE). He has supervised 28 higher degrees (Masters, PhDs and MDs, etc.).

Professor Wilding is Chair of the NIHR National Clinical Research Network Metabolic and Endocrine Specialty Group and immediate past

President of the World Obesity Federation.  

Duality of Interest:

Receipt of grants/research support from: AstraZeneca, Lilly, NovoNordisk, Rhythm (Institutional)

Receipt of honoraria/consultation fees from: Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Keros Pharamceuticals, Lilly, Novo Nordisk, Menarini, Pfizer, Rhythm, Regeneron, Saniona, Shionogi, Tern, Ysopia (all fees paid to institution)

Participation in a company sponsored speaker’s bureau: AstraZeneca, Boehringer Ingelheim

Date: March 2026